Skip to main content
Top
Gepubliceerd in:

21-12-2015 | Original Paper

Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review

Auteurs: Seema Jain, Rebecca Andridge, Jessica A. Hellings

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Loxapine substitution is a promising option for patients with autism spectrum disorder (ASD) who develop antipsychotic-induced metabolic illness. We performed a chart review of 15 adolescents and adults meeting DSM-IV-TR criteria for ASD, all with antipsychotic-associated weight gain, who received low dose loxapine in an attempt to taper or discontinue the weight gain-associated antipsychotic. Mean weight loss was −5.7 kg, mean BMI reduction was −1.9, and mean triglyceride reduction was −33.7 mg/dl. At chart review, 14 of 15 subjects were rated 2 (Much Improved) or 1 (Very Much Improved) on the Clinical Global Impressions-Improvement scale (CGI-I). Low dose loxapine addition in most cases enabled taper of offending antipsychotics, significantly reversed drug-induced metabolic disturbances and improved irritability.
Literatuur
go back to reference Alvarez-Jimenez, M., Hetrick, S. E., Gonzalez-Blanch, C., Gleeson, J. F., & McGorry, P. D. (2008). Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomized controlled trials. British Journal of Psychiatry, 193, 101–107.CrossRefPubMed Alvarez-Jimenez, M., Hetrick, S. E., Gonzalez-Blanch, C., Gleeson, J. F., & McGorry, P. D. (2008). Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomized controlled trials. British Journal of Psychiatry, 193, 101–107.CrossRefPubMed
go back to reference Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist: Manual. East Aurora, NY: Slosson Educational Publications. Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist: Manual. East Aurora, NY: Slosson Educational Publications.
go back to reference American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorder, Fourth Edition revised. Arlington, VA: American Psychiatric Association.CrossRef American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorder, Fourth Edition revised. Arlington, VA: American Psychiatric Association.CrossRef
go back to reference Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344.CrossRefPubMed Beherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. Journal of Clinical Psychopharmacology, 31(3), 341–344.CrossRefPubMed
go back to reference Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70(100), 1067–1075.CrossRefPubMed Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., et al. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70(100), 1067–1075.CrossRefPubMed
go back to reference Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473(7346), 221–225.CrossRefPubMedPubMedCentral Brennand, K. J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature, 473(7346), 221–225.CrossRefPubMedPubMedCentral
go back to reference Brooks, J. O., Chang, H. S., & Krasnykh, O. (2009). Metabolic risks in older adults receiving second-generation antipsychotic medication. Current Psychiatry Reports, 11, 33.CrossRefPubMed Brooks, J. O., Chang, H. S., & Krasnykh, O. (2009). Metabolic risks in older adults receiving second-generation antipsychotic medication. Current Psychiatry Reports, 11, 33.CrossRefPubMed
go back to reference Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17(4), 640–655.CrossRefPubMed Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17(4), 640–655.CrossRefPubMed
go back to reference Correll, C. U., Robinson, D., Schooler, N., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., et al. (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from RAISE-ETP study. JAMA Psychiatry, 71(12), 1350–1363.CrossRefPubMed Correll, C. U., Robinson, D., Schooler, N., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., et al. (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from RAISE-ETP study. JAMA Psychiatry, 71(12), 1350–1363.CrossRefPubMed
go back to reference Doss, F. W. (1979). The effect of antipsychotic drugs on body weight: A retrospective review. Journal of Clinical Pyschiatry, 40, 528. Doss, F. W. (1979). The effect of antipsychotic drugs on body weight: A retrospective review. Journal of Clinical Pyschiatry, 40, 528.
go back to reference Goudie, A. J., Cooper, G. D., & Halford, J. C. G. (2005). Antipsychotic-induced weight gain. Diabetes, Obesity and Metabolism, 7(5), 478–487.CrossRefPubMed Goudie, A. J., Cooper, G. D., & Halford, J. C. G. (2005). Antipsychotic-induced weight gain. Diabetes, Obesity and Metabolism, 7(5), 478–487.CrossRefPubMed
go back to reference Guy, W. (1976). Clinical Global Impression scale (CGI). The ECDEU Assessment Manual for Psychopharmacology-Revised, 76(338), 218–222. Guy, W. (1976). Clinical Global Impression scale (CGI). The ECDEU Assessment Manual for Psychopharmacology-Revised, 76(338), 218–222.
go back to reference Hellings, J. A., Jadhav, M., Jain, S., Jadhav, S., & Genovese, A. (2015a). Low dose loxapine: neuromotor side effects and tolerability in autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 25(8), 618–624.CrossRefPubMed Hellings, J. A., Jadhav, M., Jain, S., Jadhav, S., & Genovese, A. (2015a). Low dose loxapine: neuromotor side effects and tolerability in autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology, 25(8), 618–624.CrossRefPubMed
go back to reference Hellings, J. A., Reed, G., Cain, S. E., Zhou, X., Barth, F. X., Aman, M. G., et al. (2015b). Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. Journal of Child and Adolescent Psychopharmacology, 25(2), 150–159.CrossRefPubMedPubMedCentral Hellings, J. A., Reed, G., Cain, S. E., Zhou, X., Barth, F. X., Aman, M. G., et al. (2015b). Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. Journal of Child and Adolescent Psychopharmacology, 25(2), 150–159.CrossRefPubMedPubMedCentral
go back to reference Hellings, J. A., Zarcone, J. R., Crandall, K. C., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229–238.CrossRefPubMed Hellings, J. A., Zarcone, J. R., Crandall, K. C., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229–238.CrossRefPubMed
go back to reference Jibson, M. D. (2014). First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. In R. Herman (Ed.), UptoDate Waltham, MA. (Accessed June 17, 2014). Jibson, M. D. (2014). First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. In R. Herman (Ed.), UptoDate Waltham, MA. (Accessed June 17, 2014).
go back to reference Li, Z., Ichikawa, J., & Meltzer, H. Y. (2003). A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl), 167(3), 315–323. Li, Z., Ichikawa, J., & Meltzer, H. Y. (2003). A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl), 167(3), 315–323.
go back to reference Lieberman, J. A., & Stroup, T. S. (2011). The NIMH-CATIE Schizophrenia Study: What did we learn? American Journal of Psychiatry, 168(8), 770–775.CrossRefPubMed Lieberman, J. A., & Stroup, T. S. (2011). The NIMH-CATIE Schizophrenia Study: What did we learn? American Journal of Psychiatry, 168(8), 770–775.CrossRefPubMed
go back to reference Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76(3), 391–396.PubMed Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76(3), 391–396.PubMed
go back to reference Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 40(6), 1385–1403.CrossRefPubMedPubMedCentral Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W. W., et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: A systematic review and meta-analysis. Schizophrenia Bulletin, 40(6), 1385–1403.CrossRefPubMedPubMedCentral
go back to reference Munetz, M. R., & Benjamin, S. (1988). How to examine patients using the Abnormal Involuntary Movement Scale. Psychiatric Services, 39(11), 1172–1177.CrossRef Munetz, M. R., & Benjamin, S. (1988). How to examine patients using the Abnormal Involuntary Movement Scale. Psychiatric Services, 39(11), 1172–1177.CrossRef
go back to reference Newcomer, J., & Haupt, D. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry, 51, 480–491.PubMed Newcomer, J., & Haupt, D. (2006). The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry, 51, 480–491.PubMed
go back to reference Pramyothin, P., & Khaodhiar, L. (2010). Metabolic syndrome with the atypical antipsychotics. Current opinion in Endocrinology, Diabetes, and Obesity, 17(5), 460–466.CrossRefPubMed Pramyothin, P., & Khaodhiar, L. (2010). Metabolic syndrome with the atypical antipsychotics. Current opinion in Endocrinology, Diabetes, and Obesity, 17(5), 460–466.CrossRefPubMed
go back to reference Reinblatt, S. P., Abanilla, P. K., Jummani, R., & Coffey, B. (2006). Loxapine treatment in an Autistic child with aggressive behavior: Therapeutic challenges. Journal of Child and Adolescent Psychopharmacology, 16(5), 639–643.CrossRefPubMed Reinblatt, S. P., Abanilla, P. K., Jummani, R., & Coffey, B. (2006). Loxapine treatment in an Autistic child with aggressive behavior: Therapeutic challenges. Journal of Child and Adolescent Psychopharmacology, 16(5), 639–643.CrossRefPubMed
go back to reference Stahl, S.M. (2002). Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge: Cambridge University Press. Stahl, S.M. (2002). Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge: Cambridge University Press.
go back to reference Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide. New Delhi: Cambridge University Press. Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide. New Delhi: Cambridge University Press.
go back to reference Wetterling, T., & MuBigbrodt, H. E. (1999). Weight gain: Side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology, 19(4), 316–321.CrossRefPubMed Wetterling, T., & MuBigbrodt, H. E. (1999). Weight gain: Side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology, 19(4), 316–321.CrossRefPubMed
go back to reference Wu, R. R., Zhao, J. P., Jin, H., Shao, P., Fang, M. S., Guo, X. F., et al. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA, 299, 185–193.PubMed Wu, R. R., Zhao, J. P., Jin, H., Shao, P., Fang, M. S., Guo, X. F., et al. (2008). Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA, 299, 185–193.PubMed
Metagegevens
Titel
Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review
Auteurs
Seema Jain
Rebecca Andridge
Jessica A. Hellings
Publicatiedatum
21-12-2015
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 4/2016
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-015-2675-3

Andere artikelen Uitgave 4/2016

Journal of Autism and Developmental Disorders 4/2016 Naar de uitgave